When we examined the protein level in the cell culture mediums from TNBC organoid assays and murine blood samples from TNBC murine models upon treatment of the targeted therapies against CLU pathway via targeting CLU and/or PRKD3 compared to controls, we found that sCLU protein levels were consistently decreased upon treatment of the targeted therapies against CLU and PRKD3, which resulted in significant tumor suppression (Figure 8C–F). The gene discussed is PRKD3; the disease is neoplasm.